-
We detected your language preference as English. Would you like to switch to the English version for a better experience?
Switch to English
Stay here
Kolon TissueGene is eliminating 37 positions at its Rockville, Maryland site following a setback in the Phase 3 development of its lead cell therapy, TG-C, for knee osteoarthritis. According to a state WARN notice, the workforce reduction is expected to be completed by Aug. 31.
The cuts come shortly after the company reported that its ACTiVION-II Phase 3 trial failed to meet its co-primary endpoints. The study, the first of two U.S.-based Phase 3 trials evaluating TG-C, did not demonstrate the required improvements in pain scores or total WOMAC scores at the 12-month assessment.
Kolon TissueGene CEO Seng Ho Jeon acknowledged the disappointing results in a statement to investors, saying the outcome had caused significant concern. The company said the layoffs are part of a broader effort to realign its business and operational priorities following the clinical setback.
EMD Serono, the U.S. healthcare division of Merck KGaA, is eliminating 20 positions at its EMD Serono Research & Development Institute in Billerica, Massachusetts. According to a WARN notice, the layoffs will take effect in stages between Oct. 16 and Oct. 30.
The workforce reduction is separate from the company's previously announced plan to require approximately 70 remote employees associated with the institute to work on-site at least three days per week starting in September. That policy could lead some employees to resign and receive severance, although EMD Serono has not disclosed how many departures have occurred.
The 20 positions being eliminated span multiple functions at the research institute and include four associate directors and a global program head. The company said the restructuring is intended to better align its R&D organization with its future needs and strategy, with additional details expected in the coming months.
About a year after Sanofi completed its $9.5 billion acquisition of Blueprint Medicines, the subsidiary is cutting 229 employees at its Cambridge, Massachusetts headquarters. The layoffs are scheduled to take place between Oct. 9, 2026, and June 25, 2027, according to a state WARN notice.
Blueprint employed 687 people as of April 2025, meaning the latest workforce reduction could affect roughly one-third of its staff. The company develops treatments across allergy and inflammation as well as oncology and hematology, including Ayvakit for systemic mastocytosis, a rare blood disorder characterized by an abnormal accumulation of mast cells.
Sanofi announced the Blueprint acquisition in June 2025 and completed the transaction the following month. The deal expanded Sanofi's rare disease portfolio with Ayvakit and added Blueprint's early-stage immunology programs to the French pharma's pipeline.
MindMaze Therapeutics is eliminating a small number of positions following its reverse merger with Relief Therapeutics as the company simplifies its operations and concentrates on its core neurology business. A MindMaze executive confirmed that only a "handful" of Relief employees will be affected.
MindMaze CFO Jeremy Meinen said the company has been working to exit Relief's legacy operations while preserving as many employee positions as possible. The former Relief businesses were based at a single site in Switzerland and employed approximately 25 people.
Rather than shutting down those operations entirely, MindMaze found buyers for the businesses, allowing most of the affected employees to continue working under new ownership. Some employees also remained with MindMaze, while a small number received termination notices with separation dates several months in the future.
The transaction that created MindMaze closed in December, combining NeuroX Group's digital brain health platform with Relief's specialty biopharmaceutical operations under a publicly traded company focused on digital neurotherapeutics.
Aardvark Therapeutics has significantly reduced its workforce, with the biotech reporting 28 employees and 27 consultants as of July 31. The company confirmed that the layoffs took place in June, following a major setback for its lead program.
At the end of April, Aardvark had 40 employees and 35 consultants, indicating a substantial reduction in both its employee and contractor base over the subsequent months.
The workforce changes follow the company's decision in June to discontinue the Phase 3 HERO trial of ARD-101, an investigational treatment for hyperphagia associated with Prader-Willi syndrome. The FDA had placed the program on clinical hold in May after cardiac safety signals emerged in a healthy volunteer study involving doses above the intended therapeutic range.
Aardvark is continuing to analyze data from the HERO trial and plans to use the findings to help determine the future development strategy for ARD-101.
Aura Biosciences is reducing its workforce by approximately 20% as the company sharpens its focus on advancing its ocular oncology pipeline. With 113 employees on staff earlier this year, the restructuring could affect roughly 23 positions.
The biotech's primary focus remains the development of belzupacap sarotalocan (bel-sar), which is being evaluated for choroidal metastases, ocular surface cancers and early-stage choroidal melanoma. Aura recently completed enrollment in its Phase 3 CoMpass study and expects to report topline results from the trial's primary endpoint in the second half of 2027.
Alongside the workforce reduction, the company is scaling back investment in its non-muscle invasive bladder cancer program and implementing several leadership changes. Aura expects the restructuring to cost between $2.9 million and $3.2 million and believes the measures will extend its cash runway into the first half of 2029.
Schrödinger has carried out a targeted workforce reduction as part of a strategic shift away from independently advancing clinical-stage drug programs. The company did not disclose how many employees were affected but said the cuts were concentrated within teams supporting internal clinical development activities.
The restructuring reflects Schrödinger's decision to place greater emphasis on partnership-based development and commercialization opportunities while continuing to invest in its computational drug discovery platform and core technology capabilities.
Known for its physics-based software used in molecular modeling and drug design, Schrödinger maintains a pipeline focused largely on oncology, inflammation and immunology while collaborating with major pharmaceutical companies on drug discovery initiatives. The company previously reduced its workforce in 2025, eliminating 60 positions to lower operating expenses.
aTyr Pharma is cutting approximately 60% of its workforce as it concentrates resources on advancing its lead candidate, efzofitimod. Following the restructuring, the San Diego-based biotech expects to retain about 20 employees.
Efzofitimod is being developed for interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-associated ILD. The company is currently awaiting FDA feedback on the design of a planned Phase 3 study in pulmonary sarcoidosis while continuing a Phase 2 trial in systemic sclerosis-related ILD.
The reorganization also includes leadership changes, with Chief Financial Officer Jill Broadfoot and General Counsel Nancy Denyes set to transition out of their executive roles and become consultants. aTyr estimates the restructuring will generate annual operating expense savings of roughly $13 million and extend its cash runway into late 2028.
Arpeggio Biosciences has decided to wind down operations after encountering development challenges with its lead oncology program. The Colorado-based startup employed roughly a dozen people and is now joining a growing list of early-stage biotech companies forced to shut down amid scientific and funding pressures.
The company's most advanced asset, an NRF2 degrader for non-small cell lung cancer, ultimately failed to demonstrate a sufficiently differentiated efficacy profile from an off-target safety concern. According to CEO Joey Azofeifa, this setback made it difficult to justify continued investment in the program.
Despite its closure, Arpeggio highlighted several scientific achievements during its brief history, including the generation of millions of experimental data points, extensive transcriptomic analysis and the creation of more than 2,000 proprietary small molecules across multiple discovery programs.
Ensoma is reducing its workforce for the second time in less than a year as the Boston-based biotech concentrates its resources on its lead program and seeks additional financing. The company confirmed the restructuring on Aug. 7 but did not disclose how many employees were affected.
Under the reorganization, Ensoma is prioritizing development of EN-374 for X-linked chronic granulomatous disease (X-CGD) and clinical validation of its platform in other therapeutic areas. Investment and research on several earlier-stage programs have been put on hold while the company works to secure additional funding.
The latest cuts follow a much larger reduction in November, when Ensoma eliminated half of its workforce. The company subsequently said that 37 employees remained. EN-374, an in vivo gene insertion therapy targeting hematopoietic stem cells, entered the clinic in December after the first patient was dosed in a Phase 1/2 trial for X-CGD, a rare genetic disorder that impairs the immune system's ability to fight infections.
The programs now on pause were still in the research stage and included candidates targeting sickle cell disease, solid tumor immuno-oncology and hematologic oncology.
Emergent BioSolutions is restructuring its operations to better match current business needs, a move that will eliminate 93 jobs and 21 currently vacant positions. The changes were announced alongside the company's second-quarter financial results.
The workforce reduction represents a relatively small portion of Emergent's approximately 900 employees. The company did not identify all of the locations affected, but said the restructuring will include the closure of wet laboratories at its headquarters in Gaithersburg, Maryland.
The organizational changes will also eliminate the chief medical officer and head of research and development position, resulting in Simon Lowry's departure from Emergent on Aug. 19. At the same time, the company is establishing a new growth organization that will bring together R&D, business development and strategy. Stephanie Duatschek, previously the company's senior vice president and chief global strategy and franchise development officer, will lead the new group as executive vice president and chief growth officer.
Emergent expects the restructuring to result in approximately $10 million to $11.5 million in related costs. The company reported $139.7 million in cash and cash equivalents as of June 30.
Aurora Therapeutics is scaling back its early development strategy, discontinuing its lead gene-editing program for phenylketonuria (PKU) and laying off several employees. The decision comes as the young biotech reassesses its position in an increasingly competitive PKU research landscape.
Aurora launched in January with $16 million in seed funding from Menlo Ventures and initially focused on developing an N-of-1 gene-editing approach for PKU, a rare inherited disorder in which the body cannot properly process the amino acid phenylalanine.
The company has now decided to deprioritize the PKU program after other biotech companies began pursuing similar approaches. As a result, several members of Aurora's team have been let go, although the company has not disclosed the exact number of affected employees.
Pfizer is expanding its ongoing cost-reduction initiative by an additional $2.5 billion, with a significant portion of the savings expected to come from technology-driven efficiencies and operational simplification across its commercial, research and development, and manufacturing organizations.
As part of its "Realigning Our Cost Base Program," the company expects to generate approximately $1 billion in savings between 2027 and 2029. The initiative was outlined in Pfizer's second-quarter earnings report released on Aug. 4.
The restructuring will require substantial upfront investment, however. Pfizer estimates it will incur roughly $2 billion in one-time expenses related to digital transformation efforts, implementation costs and employee severance. The company has not disclosed whether specific positions will be eliminated or provided details regarding the scope of any workforce impact.
Lisata Therapeutics has reduced approximately 72% of its full-time workforce following the collapse of its planned merger with Kuva Labs. Based on the company's reported headcount of 21 employees at the end of 2025, the restructuring is estimated to affect around 15 positions.
The workforce reduction is intended to lower operating expenses and preserve cash while the company evaluates strategic alternatives. Lisata, which focuses on therapies for advanced solid tumors and other serious diseases, confirmed that senior leadership was also impacted, including Executive Vice President of Research and Development and Chief Medical Officer Kristen Buck.
At the same time, Lisata has filed a lawsuit against Kuva Labs, alleging that the company breached the parties' merger agreement. Lisata is seeking financial damages on behalf of its shareholders, as well as a $2 million termination fee that it claims is owed under the terms of the deal.
The planned merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals is expected to create some workforce overlap, potentially resulting in "natural redundancies" among general and administrative functions, according to Supernus CEO Jack Khattar during an Aug. 3 investor call.
The companies did not provide specific details on the number of positions that could be affected, and no additional information was included in the merger announcement or related SEC filings. Based on their latest annual reports, Supernus employed 778 people as of Dec. 31, while Indivior had a workforce of 838 employees.
The all-stock merger of equals will combine the two companies into a central nervous system–focused pharmaceutical business. The combined company is expected to generate approximately $2.2 billion in annual revenue, with projected operating earnings of around $888 million.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
